Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.
Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, Manzano JL, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Abad A, et al. Among authors: salazar r. Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737. Ann Oncol. 2018. PMID: 29145602 Free article. Clinical Trial.
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial.
Gomez-Martin C, Solá C, Hornedo J, Perea S, Lumbreras C, Valentí V, Arcediano A, Rodriguez M, Salazar R, Cortés-Funes H, Hidalgo M. Gomez-Martin C, et al. Among authors: salazar r. J Clin Oncol. 2000 May;18(10):2126-34. doi: 10.1200/JCO.2000.18.10.2126. J Clin Oncol. 2000. PMID: 10811678 Clinical Trial.
E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience.
Arranz Arija JA, García del Muro X, Gumà J, Aparicio J, Salazar R, Saenz A, Carles J, Sánchez M, Germà-Lluch JR. Arranz Arija JA, et al. Among authors: salazar r. Ann Oncol. 2001 Apr;12(4):487-91. doi: 10.1023/a:1011127715764. Ann Oncol. 2001. PMID: 11398880 Free article. Clinical Trial.
Targeted therapy in advanced colon cancer: the role of new therapies.
Tabernero J, Salazar R, Casado E, Martinelli E, Gómez P, Baselga J. Tabernero J, et al. Among authors: salazar r. Ann Oncol. 2004;15 Suppl 4:iv55-62. doi: 10.1093/annonc/mdh905. Ann Oncol. 2004. PMID: 15477336 Free article. Review. No abstract available.
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Font A, Salazar R, Maurel J, Taron M, Ramirez JL, Tabernero J, Gallego R, Casado E, Manzano JL, Carcereny E, Guix M, Fernández-Llamazares J, Rosell R. Font A, et al. Among authors: salazar r. Cancer Chemother Pharmacol. 2008 Nov;62(6):1075-83. doi: 10.1007/s00280-008-0700-3. Epub 2008 Mar 12. Cancer Chemother Pharmacol. 2008. PMID: 18335219 Clinical Trial.
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R. Garcia-Carbonero R, et al. Among authors: salazar r. Ann Oncol. 2010 Sep;21(9):1794-1803. doi: 10.1093/annonc/mdq022. Epub 2010 Feb 5. Ann Oncol. 2010. PMID: 20139156 Free article. Review.
Colorectal Cancer OncoGuia.
Manchon Walsh P, Borràs JM, Ferro T, Espinàs JA; Colorectal Cancer OncoGuia Group. Manchon Walsh P, et al. Clin Transl Oncol. 2010 Mar;12(3):188-210. doi: 10.1007/s12094-010-0489-5. Clin Transl Oncol. 2010. PMID: 20231124 No abstract available.
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer.
Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, Glas AM, Van't Veer LJ, Tollenaar R. Salazar R, et al. J Clin Oncol. 2011 Jan 1;29(1):17-24. doi: 10.1200/JCO.2010.30.1077. Epub 2010 Nov 22. J Clin Oncol. 2011. PMID: 21098318 Free article.
645 results